DK240190A - Middel og metode til acceleration af blodsammenklumpningslyse - Google Patents

Middel og metode til acceleration af blodsammenklumpningslyse Download PDF

Info

Publication number
DK240190A
DK240190A DK240190A DK240190A DK240190A DK 240190 A DK240190 A DK 240190A DK 240190 A DK240190 A DK 240190A DK 240190 A DK240190 A DK 240190A DK 240190 A DK240190 A DK 240190A
Authority
DK
Denmark
Prior art keywords
hapten
acceleration
binding molecule
thrombolytic agent
preventing
Prior art date
Application number
DK240190A
Other languages
English (en)
Other versions
DK174062B1 (da
DK240190D0 (da
Inventor
Guy L Reed
Gary Matsueda
Edgar Haber
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Publication of DK240190A publication Critical patent/DK240190A/da
Publication of DK240190D0 publication Critical patent/DK240190D0/da
Application granted granted Critical
Publication of DK174062B1 publication Critical patent/DK174062B1/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Surgical Instruments (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • External Artificial Organs (AREA)
  • Peptides Or Proteins (AREA)
DK199002401A 1988-04-04 1990-10-04 Kombineret præparat til anvendelse ved en fremgangsmåde til behandling af myocardieinfarkt DK174062B1 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US17722288A 1988-04-04 1988-04-04
US17722288 1988-04-04
PCT/US1989/001065 WO1989009817A1 (en) 1988-04-04 1989-03-15 Composition and method for acceleration of clot lysis
US8901065 1989-03-15

Publications (3)

Publication Number Publication Date
DK240190A true DK240190A (da) 1990-10-04
DK240190D0 DK240190D0 (da) 1990-10-04
DK174062B1 DK174062B1 (da) 2002-05-13

Family

ID=22647707

Family Applications (1)

Application Number Title Priority Date Filing Date
DK199002401A DK174062B1 (da) 1988-04-04 1990-10-04 Kombineret præparat til anvendelse ved en fremgangsmåde til behandling af myocardieinfarkt

Country Status (15)

Country Link
EP (1) EP0336693B1 (da)
JP (1) JP2871775B2 (da)
KR (1) KR100194113B1 (da)
AT (1) ATE114480T1 (da)
AU (1) AU628041B2 (da)
CA (1) CA1341377C (da)
DE (1) DE68919504T2 (da)
DK (1) DK174062B1 (da)
ES (1) ES2064435T3 (da)
FI (1) FI102812B1 (da)
GR (1) GR3015182T3 (da)
HU (1) HU207349B (da)
NO (1) NO301374B1 (da)
WO (1) WO1989009817A1 (da)
ZA (1) ZA892464B (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5357042A (en) * 1984-04-23 1994-10-18 The General Hospital Corporation Synthetic peptides capable of eliciting fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity
US5453269A (en) * 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5609869A (en) * 1988-08-19 1997-03-11 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
JPH02268694A (ja) * 1989-04-07 1990-11-02 Teijin Ltd 血栓溶解剤
JP2001515345A (ja) * 1996-09-20 2001-09-18 ザ・ジェネラル・ホスピタル・コーポレイション アルファ―２―抗プラスミンに対する抗体を用いてフィブリン溶解を増進するための組成物と方法
US6524675B1 (en) 1999-05-13 2003-02-25 3M Innovative Properties Company Adhesive-back articles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0735340B2 (ja) * 1985-05-23 1995-04-19 帝人株式会社 血栓溶解促進剤
DE3751907T2 (de) * 1986-05-15 1997-04-03 Univ Emory Injizierbares Arzneimittel zum Schutz vor Gewebebeschädigung durch Ischemie

Also Published As

Publication number Publication date
JP2871775B2 (ja) 1999-03-17
KR100194113B1 (ko) 1999-06-15
DK174062B1 (da) 2002-05-13
HU892304D0 (en) 1991-07-29
ES2064435T3 (es) 1995-02-01
AU628041B2 (en) 1992-09-10
FI102812B (fi) 1999-02-26
ATE114480T1 (de) 1994-12-15
NO301374B1 (no) 1997-10-20
EP0336693A3 (en) 1990-03-21
HU207349B (en) 1993-03-29
AU3284589A (en) 1989-11-03
NO904294L (no) 1990-12-04
WO1989009817A1 (en) 1989-10-19
DE68919504D1 (de) 1995-01-12
GR3015182T3 (en) 1995-05-31
JPH03504717A (ja) 1991-10-17
DE68919504T2 (de) 1995-06-29
ZA892464B (en) 1989-12-27
EP0336693B1 (en) 1994-11-30
NO904294D0 (no) 1990-10-03
EP0336693A2 (en) 1989-10-11
FI904867A0 (fi) 1990-10-03
HUT56394A (en) 1991-08-28
DK240190D0 (da) 1990-10-04
KR900700129A (ko) 1990-08-11
FI102812B1 (fi) 1999-02-26
CA1341377C (en) 2002-07-16

Similar Documents

Publication Publication Date Title
NO885109L (no) Fremgangsmaate og middel for aa forhindre blodpropp.
Seitz et al. Increased thrombin activity during thrombolysis
DK240190A (da) Middel og metode til acceleration af blodsammenklumpningslyse
BR9708859A (pt) Composto uso do mesmo composição para inibir formação de trombo em sangue e processos para inibir trombina e formação de agregados de plaquetas sanguíneas e de trombo no sangue para tratar ou evitar tromboemolismo venoso e embolismo pulmonar trombose tromboembolismo cardiogênico acidente vascular cerebral trombose angina instável infartação miocárdica aterosclerose distúrbio cardaco isquêmico reoclus o restenose oclus o de enxertos de derivação de artéria coronária e doença cerebrovascular oclus
DK36991D0 (da) Vaevsplasminoaktivator-(t-pa)-variant med zymogene eller fibrinspecifikke eller plasmakoagel-specifikke egenskaber, fremgangsmaade til fremstilling deraf, dna-sekvens, som koder for varianten, replicerbar udtrykkelsesvektor for denne og vaertsceller transformeret med vektoren
DK0788546T3 (da) Nematode-ekstraherede serinproteaseinhibitorer og antikoagulerende proteiner
ATE250604T1 (de) Pyridyl enthaltende spirocyclische verbindungen als inhibitoren der fibrinogen-abhängigen blutplättchen aggregation
ATE73332T1 (de) Neuartige verwendung von taurolin.
ES2076965T3 (es) Activadores del plasminogeno salivares del murcielago vampiro.
DE68919311D1 (de) Selbstinduzierte Reparatur von Leiterzügen.
DK226889A (da) Alkoholpeptidderivat samt anvendelse deraf til mindskning af blodkoagulation
Marci et al. A review of the clinical indications for the plasma heparin assay
ATE84724T1 (de) Gewisse paf-antagonist/antihistamin-mischungen und verfahren.
ATE440108T1 (de) Plasmin-inhibitoren von der australischen braunen schlange, pseudonaja textilis textilis
Preissner et al. Influence of fibrinogen on fibrin polymerization. Ultracentrifugation studies
Jang et al. A randomized, blinded study of two doses of Novastan®(brand of argatroban) versus heparin as adjunctive therapy to recombinant tissue plasminogen activator (accelerated administration) in acute myocardial infarction: Rationale and design of the Myocardial Infarction using Novastan® and t-PA (MINT) study
ATE175243T1 (de) Verwendung von prothrombinfragmenten
DK0525252T3 (da) Anvendelse af stafylokinase til fremstilling af en farmaceutisk sammensætning til behandling af arteriel thrombose.
Konttinen The effect of streptokinase on the plasma heparin thrombin time
Atkinson THE COAGULANT ACTION OF DISPHOLIDUS TYPUS (BOOMSLANG) VENOM.
SHIMIZU Studies on the Disturbance in Blood Clotting Following Massive Transfusion of Preserved Blood Part I. Experimental Investigation on the Mechanism of Disturbed Blood Clotting Following Massive Transfusion of Preserved Blood
IT1133037B (it) Sistema elettronico per la determinazione del tempo di coagulazione del plasma e per la determinazione della concentrazione plasmatica di fibrinogeno

Legal Events

Date Code Title Description
PBP Patent lapsed

Country of ref document: DK